Let me gather a bit more — analyst ratings/price targets and any life science sector commentary, plus check the interest coverage / debt maturity data point mentioned in Yahoo teaser.# Healthpeak Properties (DOC) — Q2 2026 Earnings Preview
Report date: Tuesday, August 4, 2026, after market close | Call: Wednesday, August 5, 10:00 a.m. ET
Snapshot
|
|
| Stock price (8/3/26 close) |
~$21.65 |
| YTD move |
~+34% (from ~$16.20 on 1/2/26) |
| Move since Q1 print (5/5→5/6) |
+18% same-day pop on beat/raise |
| Dividend |
$0.10167/month ($1.22 annualized), maintained for Q3 |
| Net Debt / Adjusted EBITDAre (Q1'26) |
5.4x |
| FY2026 guidance (company) |
FFO as Adjusted $1.71–$1.75/share |
| Q2'26 consensus (Zacks) |
FFOA ~$0.44/share (-4.4% y/y); revenue ~$726M (+4.6% y/y) |
Healthpeak is a diversified healthcare REIT operating across three segments: Outpatient Medical, Lab (life science), and Senior Housing — the last of which is now run through its ~82%-owned, separately-listed subsidiary Janus Living (NYSE: JAN), which IPO'd in March 2026.
Where things stood after Q1
Q1 2026 was a strong, transaction-heavy quarter. Healthpeak reported net income of $0.28 per share, Nareit FFO of $0.42 per share, and FFO as Adjusted of $0.45 per share, comfortably ahead of expectations, and total revenue rose to roughly $753 million from $703 million a year earlier. The stock jumped from ~$16.50 to ~$19.50 the day results hit — an 18% pop — as investors digested several capital-allocation wins:
- Gateway campus (South San Francisco): CEO Scott Brinker called it a "once-in-a-decade buying opportunity" acquired for a fraction of replacement cost, already generating leasing momentum.
- Janus Living IPO: completed at the high end of the range, generating approximately $880 million of net proceeds in an oversubscribed and upsized offering, with Healthpeak retaining an 81.6% stake.
- Blackstone JV recap: a fully-occupied outpatient portfolio recapitalized at a gross valuation of $212 million, generating ~$170 million of proceeds at a 6.1% cash cap rate — described by management as a "template for future recaps and acquisitions with Blackstone."
- Buybacks: $100 million of stock repurchased in April at a weighted average price of $16.81, which management called accretive at a "10-plus percent FFO yield."
Segment-level same-store cash NOI told a split story: Outpatient Medical +2.4%, Senior Housing +13.8%, but Lab -7.2%, netting to flat (0.0%) total same-store growth. Management raised full-year FFOA guidance to $1.71–$1.75/share while reaffirming same-store NOI guidance of (1.0%)–1.0%.
What's happened since the Q1 call (the real story for this print)
Three months of aggressive capital recycling and a big stock re-rating set up this report:
- Brookfield JV (July 20): Healthpeak formed a new $2.1 billion strategic joint venture with Brookfield Asset Management, contributing 86 outpatient medical buildings (~5.6 million sq ft, 95% leased) in exchange for a 49% stake sale. Healthpeak retained 51% control and management fees, generated ~$1.025 billion of gross proceeds at a 5.9% cash cap rate (~$380/sq ft), and kept a call right to buy back Brookfield's stake after year seven. This is effectively the second major institutional capital partnership in 2026 (after Blackstone), reinforcing management's stated strategy of monetizing its outpatient platform at valuations "inside" what the public market implies for the stock.
- Dividend maintained: On July 9, the board declared the Q3 monthly dividend unchanged at $0.10167/share ($1.22 annualized) — signaling no near-term change to the payout despite the stock's rally (yield has compressed from ~7.4% in the low-$16s to ~5.6% at ~$21.65 today).
- Big stock re-rating: Shares climbed from ~$16.50 pre-Q1 print to a 2026 high near $22.82 (July 28) before pulling back modestly to ~$21.65 into this print — a run of roughly +30-34% since the last earnings release, meaningfully outpacing the sector. That raises the bar: consensus now looks for a sequential/annual FFOA decline, so the market will be watching for confirmation that fundamentals (not just deal-making) are catching up to the valuation.
- Debt refinancing overhang: On the Q1 call, CFO Kelvin Moses and CEO Brinker flagged $650 million of 3.5% senior notes maturing in June 2026 as a second-half interest-expense headwind since they'll be refinanced at materially higher current rates — this should show up in Q2/Q3 interest expense and is a key line to check against guidance.
Key things to watch in the Q2 print
- Lab occupancy trajectory: Management guided to at least 100bps of total lab occupancy improvement by year-end 2025→2026, ending Q1 at 77.7% total occupancy, with ~400,000 sq ft of 2026 expirations offset by ~500,000+ sq ft of known commencements. Watch whether net absorption is tracking to plan and whether cash re-leasing spreads (3.5% in Q1, ~5% trailing-12-month) are holding up as biotech capital markets activity — described as the "most active month for biotech equity issuance since early 2021" in April — feeds through to actual leases signed.
- Same-store NOI cadence: With Outpatient Medical positive, Lab negative, and Senior Housing very strong in Q1, the blended print was flat. Any signs of Lab same-store stabilizing (or Senior Housing decelerating post-IPO comparisons) will move the full-year (-1%/+1%) same-store guidance.
- Interest expense/guidance bridge: How the June refinancing of the $650M 3.5% notes lands, plus the $400M delayed-draw term loan (undrawn as of Q1) — both flagged as swing factors for H2 earnings cadence, which management said should run close to $0.43/share per quarter at the guidance midpoint.
- Capital recycling pace and use of proceeds: Between Q1 dispositions/recaps (~$267M), the Blackstone JV (~$170M) and now the Brookfield JV (~$1.025B), Healthpeak looks to be running well ahead of its stated $1 billion 2026 recycling target. The key question is capital allocation from here — more buybacks (though at a much higher share price than April's $16.81), additional lab/outpatient acquisitions, deleveraging, or funding Janus Living's growth.
- Janus Living (JAN) contribution: As ~82% owner, Healthpeak's consolidated results are increasingly levered to Janus Living's senior-housing performance (Q1 revenue +35%, Adjusted EBITDAre +42% y/y). Management guided to the IPO being roughly earnings-neutral to Healthpeak in 2026 and accretive (~$0.03–$0.04/share) in 2027 as IPO cash and acquisitions stabilize — watch for confirmation of that trajectory and any update on the ~$400 million of senior-housing acquisitions Janus had under contract.
- Buyback economics revisited: Management was explicit that the stock was "mispriced versus intrinsic value" at ~$16-17 and worth buying back; with shares now ~30% higher, commentary on whether buybacks remain attractive (vs. deploying into lab/outpatient deals or new JVs) will be a useful read on management's view of current valuation.
Estimates going in
- Q2 FFO as Adjusted: Zacks consensus ~$0.44/share, implying a 4.4% year-over-year decline from $0.46 (largely reflecting Janus Living NCI deduction dynamics and the absence of one-time gains, not underlying operating deterioration).
- Q2 Revenue: Consensus around $726 million, up ~4.6% year-over-year.
- FY2026: Company guidance of $1.71–$1.75/share FFOA remains the anchor; consensus sits near the upper end of that range, implying a modest year-over-year decline from FY2025's ~$1.84, driven by the Janus Living IPO/consolidation mechanics rather than a fundamental slowdown.
- Healthpeak has beaten or met Street FFOA estimates in each of the last several quarters, including a ~4.7% beat in Q1 2026, though the model does not point to a clear beat this quarter given how closely the estimate has held steady.
Bottom line
This is a "show me the fundamentals" quarter after a deal-and-rally-driven stretch. The Q1 print was won largely on capital-markets execution (Janus Living IPO, Blackstone JV, Gateway acquisition, buybacks), and that playbook has continued — most notably the $2.1 billion Brookfield JV in July, which generated another ~$1 billion of proceeds at a sub-6% cap rate and validates private-market demand for Healthpeak's outpatient platform. With the stock up over 30% since the last report and trading near 2026 highs, the market has largely priced in continued deal flow; the incremental swing factors for Q2 are whether Lab occupancy/leasing spreads are genuinely inflecting, how much the June note refinancing dents H2 interest expense, and whether Janus Living's senior-housing momentum is sustaining the accretion math management laid out for 2027. A clean beat-and-raise with visible Lab stabilization would support further re-rating; a soft same-store number or bigger-than-expected interest-expense drag could trigger profit-taking after such a sharp run.